Literature DB >> 18783339

Ceramide in bacterial infections and cystic fibrosis.

Heike Grassmé1, Katrin Anne Becker, Yang Zhang, Erich Gulbins.   

Abstract

Ceramide is formed by the activity of sphingomyelinases, by degradation of complex sphingolipids, reverse ceramidase activity or de novo synthesized. The formation of ceramide within biological membranes results in the formation of large ceramide-enriched membrane domains. These domains serve the spatial and temporal organization of receptors and signaling molecules. The acid sphingomyelinase-ceramide system plays an important role in the infection of mammalian host cells with bacterial pathogens such as Neisseria gonorrhoeae, Escherichia coli, Staphylococcus aureus, Listeria monocytogenes, Salmonella typhimurium and Pseudomonas aeruginosa. Ceramide and ceramide-enriched membrane platforms are also involved in the induction of apoptosis in infected cells, such as in epithelial and endothelial cells after infection with Pseudomonas aeruginosa and Staphylococcus aureus, respectively. Finally, ceramide-enriched membrane platforms are critical regulators of the release of pro-inflammatory cytokines upon infection. The diverse functions of ceramide in bacterial infections suggest that ceramide and ceramide-enriched membrane domains are key players in host responses to many pathogens and thus are potential novel targets to treat infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783339     DOI: 10.1515/BC.2008.162

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  18 in total

1.  SrfJ, a Salmonella type III secretion system effector regulated by PhoP, RcsB, and IolR.

Authors:  Mar Cordero-Alba; Joaquín Bernal-Bayard; Francisco Ramos-Morales
Journal:  J Bacteriol       Date:  2012-06-01       Impact factor: 3.490

2.  Linoleic acid supplement in cystic fibrosis: friend or foe?

Authors:  Neeraj Vij
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-13       Impact factor: 5.464

Review 3.  Ceramide-rich platforms in transmembrane signaling.

Authors:  Branka Stancevic; Richard Kolesnick
Journal:  FEBS Lett       Date:  2010-02-20       Impact factor: 4.124

4.  Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.

Authors:  Jeff Rappaport; Rachel L Manthe; Carmen Garnacho; Silvia Muro
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

5.  How Carrier Size and Valency Modulate Receptor-Mediated Signaling: Understanding the Link between Binding and Endocytosis of ICAM-1-Targeted Carriers.

Authors:  Daniel Serrano; Rachel L Manthe; Eden Paul; Rishi Chadha; Silvia Muro
Journal:  Biomacromolecules       Date:  2016-09-15       Impact factor: 6.988

6.  The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential.

Authors:  Manish Bodas; Neeraj Vij
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

Review 7.  Lipid raft redox signaling: molecular mechanisms in health and disease.

Authors:  Si Jin; Fan Zhou; Foad Katirai; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

8.  Caveolin-1 modifies the immunity to Pseudomonas aeruginosa.

Authors:  Mihaela Gadjeva; Catherine Paradis-Bleau; Gregory P Priebe; Raina Fichorova; Gerald B Pier
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

9.  Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.

Authors:  Maria Ansar; Daniel Serrano; Iason Papademetriou; Tridib Kumar Bhowmick; Silvia Muro
Journal:  ACS Nano       Date:  2013-11-20       Impact factor: 15.881

Review 10.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.